Oxygen transport from the lungs to body tissue can be monitored by measuring various physiological parameters. For example, oxygen saturation of arterial blood (SaO2) is a measure of the ratio of oxyhemoglobin (HbO2) concentration to the sum of HbO2 and deoxyhemoglobin (Hb) concentrations in the arterial blood. Because HbO2 is the major oxygen carrying component of blood, SaO2 is indicative of oxygen delivery to body tissues. As another example, oxygen saturation of venous blood (SvO2) is a similar measure of HbO2 and Hb concentrations in venous blood and is indicative of oxygen consumption by body tissues. Measurements of the concentrations of carboxyhemoglobin (HbCO) and methemoglobin (MetHb) are indicative of abnormal hemoglobin constituents that interfere with oxygen transport.
Pulse oximetry is a noninvasive, easy to use, inexpensive procedure for measuring the oxygen saturation level of arterial blood. Pulse oximeters perform a spectral analysis of the pulsatile component of arterial blood in order to determine oxygen saturation (SpaO2), which is an estimate of SaO2. A pulse oximetry system has a sensor and a monitor. The sensor has emitters that typically consist of a red light emitting diode (LED) and an infrared LED that project light through blood vessels and capillaries underneath a tissue site, such as a fingernail bed. A sensor also has a detector that typically is a photodiode positioned opposite the LEDs so as to detect the emitted light as it emerges from the tissue site. A pulse oximetry sensor is described in U.S. Pat. No. 6,088,607 entitled “Low Noise Optical Probe,” which is assigned to Masimo Corporation, Irvine, Calif. and incorporated by reference herein.
One aspect of a physiological parameter tracking system comprises a physiological signal and first, second, third and fourth calculators. The physiological signal has at least first and second intensity signal components received from a light-sensitive detector that detects light of at least first and second wavelengths transmitted through body tissue carrying pulsing blood. The first calculator is configured to output a reference parameter responsive to the physiological signal. The second calculator is configured to output an ancillary parameter responsive to the physiological signal. The third calculator is configured to output a slow parameter that is a function of the reference parameter and the ancillary parameter. The slow parameter is a function of time that is slowly varying relative to the reference parameter and the ancillary parameter. A fourth calculator is configured to output a physiological measurement responsive to the reference parameter and the slow parameter. In an embodiment, the fourth calculator provides a physiological measurement that is at least in part a function of the reference parameter and the slow parameter. In an embodiment, the physiological measurement is a function of the reference parameter and the slow parameter during a first time interval and is the ancillary parameter during a second time interval. In an embodiment, the first time interval includes a period when calculations of the ancillary parameter are unfavorable. In an embodiment, the second time interval includes a period when calculations of the ancillary parameter are favorable.
Another aspect of a physiological parameter tracking system comprises inputting a physiological signal, deriving a physiological measurement from the physiological signal during a favorable condition, estimating the physiological measurement during an unfavorable condition and outputting a combination of the derived physiological measurement and the estimated physiological measurement. In an embodiment, estimating comprises calculating a slow parameter that is physiologically related to the reference parameter and the physiological measurement and tracking the reference parameter with the slow parameter. In an embodiment, outputting comprises selecting between estimated physiological measurement and derived measurement according to the favorable condition and the unfavorable condition. In an embodiment, the favorable condition and the unfavorable conditions relate to power consumption goals. In an embodiment, the favorable condition and the unfavorable conditions relate to the quality of the physiological signal.
A further aspect of a physiological parameter tracking system comprises a physiological signal input, a reference parameter calculator and a physiological measurement means for outputting and estimating. The physiological signal input has at least first and second intensity signal components received from a light-sensitive detector that detects light of at least first and second wavelengths transmitted through body tissue carrying pulsing blood. The reference parameter calculator is configured to output a reference parameter responsive to the physiological signal. The physiological measurement means outputs a physiological parameter derived from the physiological signal input during a favorable condition and estimates the physiological parameter according to the reference parameter during an unfavorable condition. In an embodiment, a slow parameter means relates the reference parameter to the physiological parameter during the unfavorable condition. In an embodiment, an update means selects a first time period for outputting the derived physiological parameter and a second time period for outputting the estimated physiological parameter.
Overview
In one embodiment, the slow parameter is HbCO or MetHb, and the reference parameter is SpaO2. Accordingly, the physiological measurement is SpaO2 corrected for the presence of one or both of these abnormal hemoglobin constituents. In another embodiment, the slow parameter is Δav=SpaO2−SvO2, a measure of oxygen consumption at a tissue site, and the reference parameter is SpaO2. Accordingly, the physiological measurement is an estimate of SvO2.
Slow Parameter Calculation
As shown in
Also shown in
Further shown in
Tracking Examples
As shown in
As shown in
The “track” periods 332, 336 are so named because the slow parameter calculation 20 (
Also shown in
Further shown in
Ancillary Parameter Calculation
As an example, the ancillary parameter calculation 50 may include algorithms that operate on the physiological signal 02 to intermittently calculate venous oxygen saturation, SpvO2, as determined by a S/H update command 04. A corresponding slow parameter function 60 is the difference between an SpaO2 reference parameter 12 and the SpvO2 ancillary parameter 52 to yield a Δav slow parameter 22. Then, the tracking function 30 is a difference between the SpaO2 reference parameter 12 and the sampled Δav slow parameter 22 to generate a SpvO2′ physiological measurement 08. That is, the physiological measurement 08 in this example advantageously provides a continuous measurement of venous saturation SpvO2′ utilizing intermittent calculations of SpvO2. Apparatus and methods for determining SpvO2 from mechanical or ventillator induced perturbation of the venous blood volume are described in U.S. Pat. No. 5,638,816 entitled “Active Pulse Blood Constituent Monitoring” and U.S. Pat. No. 6,334,065 entitled “Stereo Pulse Oximeter,” which are assigned to Masimo Corporation, Irvine, Calif. and are incorporated by reference herein.
As an example, the ancillary parameter calculation 50 may continuously calculate venous oxygen saturation, SpvO2, as determined by the update command 04 during track periods, and this calculation is provided as the physiological measurement 08. However, during hold periods of the update command 04, the physiological measurement 08 becomes SpvO2′ i.e. the SpaO2 reference parameter 12 minus a maintained value of the Δav slow parameter 22. The physiological measurement 08 in this example advantageously provides a measurement of venous saturation that is continuous through drop-out periods.
A physiological parameter tracking system has been disclosed in detail in connection with various embodiments. These embodiments are disclosed by way of examples only and are not to limit the scope of the claims that follow. One of ordinary skill in the art will appreciate many variations and modifications.
This application claims priority benefit under 35 U.S.C.§120 from, and is a continuation of U.S. patent application Ser. No. 11/834,602, filed Aug. 6, 2007, entitled “Physiological Parameter Tracking System”, which is a continuation of U.S. patent application Ser. No. 10/930,048, filed Aug. 30, 2004, entitled “Physiological Parameter Tracking System”, which claims priority benefit under 35 U.S.C.§119(e) from U.S. Provisional Patent Application No. 60/498,749, filed Aug. 28, 2003, entitled “Physiological Parameter Tracking System”. The present application incorporates the foregoing disclosures herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
4407290 | Wilber | Oct 1983 | A |
4603700 | Nichols et al. | Aug 1986 | A |
4960128 | Gordon et al. | Oct 1990 | A |
4964408 | Hink et al. | Oct 1990 | A |
5041187 | Hink et al. | Aug 1991 | A |
5069213 | Polczynski | Dec 1991 | A |
5101825 | Gravenstein et al. | Apr 1992 | A |
5163438 | Gordon et al. | Nov 1992 | A |
5337744 | Branigan | Aug 1994 | A |
5341805 | Stavridi et al. | Aug 1994 | A |
D353195 | Savage et al. | Dec 1994 | S |
D353196 | Savage et al. | Dec 1994 | S |
5377676 | Vari et al. | Jan 1995 | A |
D359546 | Savage et al. | Jun 1995 | S |
5431170 | Mathews | Jul 1995 | A |
D361840 | Savage et al. | Aug 1995 | S |
D362063 | Savage et al. | Sep 1995 | S |
5452717 | Branigan et al. | Sep 1995 | A |
D363120 | Savage et al. | Oct 1995 | S |
5456252 | Vari et al. | Oct 1995 | A |
5482036 | Diab et al. | Jan 1996 | A |
5490505 | Diab et al. | Feb 1996 | A |
5494043 | O'Sullivan et al. | Feb 1996 | A |
5533511 | Kaspari et al. | Jul 1996 | A |
5561275 | Savage et al. | Oct 1996 | A |
5562002 | Lalin | Oct 1996 | A |
5590649 | Caro et al. | Jan 1997 | A |
5602924 | Durand et al. | Feb 1997 | A |
5632272 | Diab et al. | May 1997 | A |
5638816 | Kiani-Azarbayjany et al. | Jun 1997 | A |
5638818 | Diab et al. | Jun 1997 | A |
5645440 | Tobler et al. | Jul 1997 | A |
5685299 | Diab et al. | Nov 1997 | A |
D393830 | Tobler et al. | Apr 1998 | S |
5743262 | Lepper, Jr. et al. | Apr 1998 | A |
5746697 | Swedlow et al. | May 1998 | A |
5758644 | Diab et al. | Jun 1998 | A |
5760910 | Lepper, Jr. et al. | Jun 1998 | A |
5769785 | Diab et al. | Jun 1998 | A |
5782757 | Diab et al. | Jul 1998 | A |
5785659 | Caro et al. | Jul 1998 | A |
5788647 | Eggers | Aug 1998 | A |
5791347 | Flaherty et al. | Aug 1998 | A |
5810734 | Caro et al. | Sep 1998 | A |
5823950 | Diab et al. | Oct 1998 | A |
5830131 | Caro et al. | Nov 1998 | A |
5833618 | Caro et al. | Nov 1998 | A |
5842979 | Jarman | Dec 1998 | A |
5853364 | Baker et al. | Dec 1998 | A |
5860919 | Kiani-Azarbayjany et al. | Jan 1999 | A |
5890929 | Mills et al. | Apr 1999 | A |
5904654 | Wohltmann et al. | May 1999 | A |
5919134 | Diab | Jul 1999 | A |
5934925 | Tobler et al. | Aug 1999 | A |
5940182 | Lepper, Jr. et al. | Aug 1999 | A |
5995855 | Kiani et al. | Nov 1999 | A |
5997343 | Mills et al. | Dec 1999 | A |
6002952 | Diab et al. | Dec 1999 | A |
6011986 | Diab et al. | Jan 2000 | A |
6027452 | Flaherty et al. | Feb 2000 | A |
6036642 | Diab et al. | Mar 2000 | A |
6045509 | Caro et al. | Apr 2000 | A |
6067462 | Diab et al. | May 2000 | A |
6081735 | Diab et al. | Jun 2000 | A |
6088607 | Diab et al. | Jul 2000 | A |
6110522 | Lepper, Jr. et al. | Aug 2000 | A |
6124597 | Shehada | Sep 2000 | A |
6144868 | Parker | Nov 2000 | A |
6151516 | Kiani-Azarbayjany et al. | Nov 2000 | A |
6152754 | Gerhardt et al. | Nov 2000 | A |
6157850 | Diab et al. | Dec 2000 | A |
6165005 | Mills et al. | Dec 2000 | A |
6184521 | Coffin, IV et al. | Feb 2001 | B1 |
6206830 | Diab et al. | Mar 2001 | B1 |
6229856 | Diab et al. | May 2001 | B1 |
6232609 | Snyder et al. | May 2001 | B1 |
6236872 | Diab et al. | May 2001 | B1 |
6241683 | Macklem et al. | Jun 2001 | B1 |
6256523 | Diab et al. | Jul 2001 | B1 |
6263222 | Diab et al. | Jul 2001 | B1 |
6278522 | Lepper, Jr. et al. | Aug 2001 | B1 |
6280213 | Tobler et al. | Aug 2001 | B1 |
6285896 | Tobler et al. | Sep 2001 | B1 |
6321100 | Parker | Nov 2001 | B1 |
6334065 | Al-Ali et al. | Dec 2001 | B1 |
6343224 | Parker | Jan 2002 | B1 |
6349228 | Kiani et al. | Feb 2002 | B1 |
6360114 | Diab et al. | Mar 2002 | B1 |
6368283 | Xu et al. | Apr 2002 | B1 |
6371921 | Caro et al. | Apr 2002 | B1 |
6377829 | Al-Ali | Apr 2002 | B1 |
6388240 | Schulz et al. | May 2002 | B2 |
6397091 | Diab et al. | May 2002 | B2 |
6430525 | Weber et al. | Aug 2002 | B1 |
6463311 | Diab | Oct 2002 | B1 |
6470199 | Kopotic et al. | Oct 2002 | B1 |
6501975 | Diab et al. | Dec 2002 | B2 |
6505059 | Kollias et al. | Jan 2003 | B1 |
6515273 | Al-Ali | Feb 2003 | B2 |
6519487 | Parker | Feb 2003 | B1 |
6525386 | Mills et al. | Feb 2003 | B1 |
6526300 | Kiani et al. | Feb 2003 | B1 |
6541756 | Schulz et al. | Apr 2003 | B2 |
6542764 | Al-Ali et al. | Apr 2003 | B1 |
6580086 | Schulz et al. | Jun 2003 | B1 |
6584336 | Ali et al. | Jun 2003 | B1 |
6595316 | Cybulski et al. | Jul 2003 | B2 |
6597932 | Tian et al. | Jul 2003 | B2 |
6597933 | Kiani et al. | Jul 2003 | B2 |
6606511 | Ali et al. | Aug 2003 | B1 |
6632181 | Flaherty et al. | Oct 2003 | B2 |
6639668 | Trepagnier | Oct 2003 | B1 |
6640116 | Diab | Oct 2003 | B2 |
6643530 | Diab et al. | Nov 2003 | B2 |
6650917 | Diab et al. | Nov 2003 | B2 |
6654624 | Diab et al. | Nov 2003 | B2 |
6658276 | Kianl et al. | Dec 2003 | B2 |
6661161 | Lanzo et al. | Dec 2003 | B1 |
6671531 | Al-Ali et al. | Dec 2003 | B2 |
6678543 | Diab et al. | Jan 2004 | B2 |
6684090 | Ali et al. | Jan 2004 | B2 |
6684091 | Parker | Jan 2004 | B2 |
6697656 | Al-Ali | Feb 2004 | B1 |
6697657 | Shehada et al. | Feb 2004 | B1 |
6697658 | Al-Ali | Feb 2004 | B2 |
RE38476 | Diab et al. | Mar 2004 | E |
6699194 | Diab et al. | Mar 2004 | B1 |
6714804 | Al-Ali et al. | Mar 2004 | B2 |
RE38492 | Diab et al. | Apr 2004 | E |
6721582 | Trepagnier et al. | Apr 2004 | B2 |
6721585 | Parker | Apr 2004 | B1 |
6725075 | Al-Ali | Apr 2004 | B2 |
6728560 | Kollias et al. | Apr 2004 | B2 |
6735459 | Parker | May 2004 | B2 |
6745060 | Diab et al. | Jun 2004 | B2 |
6754516 | Mannheimer | Jun 2004 | B2 |
6760607 | Al-Ali | Jul 2004 | B2 |
6770028 | Ali et al. | Aug 2004 | B1 |
6771994 | Kiani et al. | Aug 2004 | B2 |
6792300 | Diab et al. | Sep 2004 | B1 |
6813511 | Diab et al. | Nov 2004 | B2 |
6816741 | Diab | Nov 2004 | B2 |
6822564 | Al-Ali | Nov 2004 | B2 |
6826419 | Diab et al. | Nov 2004 | B2 |
6830711 | Mills et al. | Dec 2004 | B2 |
6850787 | Weber et al. | Feb 2005 | B2 |
6850788 | Al-Ali | Feb 2005 | B2 |
6852083 | Caro et al. | Feb 2005 | B2 |
6861639 | Al-Ali | Mar 2005 | B2 |
6898452 | Al-Ali et al. | May 2005 | B2 |
6920345 | Al-Ali et al. | Jul 2005 | B2 |
6931268 | Kiani-Azarbayjany et al. | Aug 2005 | B1 |
6934570 | Kiani et al. | Aug 2005 | B2 |
6939305 | Flaherty et al. | Sep 2005 | B2 |
6943348 | Coffin IV | Sep 2005 | B1 |
6950687 | Al-Ali | Sep 2005 | B2 |
6961598 | Diab | Nov 2005 | B2 |
6970792 | Diab | Nov 2005 | B1 |
6979812 | Al-Ali | Dec 2005 | B2 |
6985764 | Mason et al. | Jan 2006 | B2 |
6990426 | Yoon et al. | Jan 2006 | B2 |
6993371 | Kiani et al. | Jan 2006 | B2 |
6996427 | Ali et al. | Feb 2006 | B2 |
6999904 | Weber et al. | Feb 2006 | B2 |
7003338 | Weber et al. | Feb 2006 | B2 |
7003339 | Diab et al. | Feb 2006 | B2 |
7015451 | Dalke et al. | Mar 2006 | B2 |
7024233 | Ali et al. | Apr 2006 | B2 |
7027849 | Al-Ali | Apr 2006 | B2 |
7030749 | Al-Ali | Apr 2006 | B2 |
7039449 | Al-Ali | May 2006 | B2 |
7041060 | Flaherty et al. | May 2006 | B2 |
7044918 | Diab | May 2006 | B2 |
7067893 | Mills et al. | Jun 2006 | B2 |
7096052 | Mason et al. | Aug 2006 | B2 |
7096054 | Abdul-Hafiz et al. | Aug 2006 | B2 |
7132641 | Schulz et al. | Nov 2006 | B2 |
7142901 | Kiani et al. | Nov 2006 | B2 |
7149561 | Diab | Dec 2006 | B2 |
7186966 | Al-Ali | Mar 2007 | B2 |
7190261 | Al-Ali | Mar 2007 | B2 |
7215984 | Diab | May 2007 | B2 |
7215986 | Diab | May 2007 | B2 |
7221971 | Diab | May 2007 | B2 |
7225006 | Al-Ali et al. | May 2007 | B2 |
7225007 | Al-Ali | May 2007 | B2 |
RE39672 | Shehada et al. | Jun 2007 | E |
7239905 | Kiani-Azarbayjany et al. | Jul 2007 | B2 |
7245953 | Parker | Jul 2007 | B1 |
7254431 | Al-Ali et al. | Aug 2007 | B2 |
8385995 | Al-Ali et al. | Feb 2013 | B2 |
20040034294 | Kimball | Feb 2004 | A1 |
Entry |
---|
Schuman, Andrew J., M.D., “Pulse oximetry: The fifth vital sign,”available at: http://contemporarypediatrics.modernmedicine.com/contemporary-pediatrics/news/pulse-oximetry-fifth-vital-sign?page=full. Oct. 1, 2014. |
Number | Date | Country | |
---|---|---|---|
20130274572 A1 | Oct 2013 | US |
Number | Date | Country | |
---|---|---|---|
60498749 | Aug 2003 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 11834602 | Aug 2007 | US |
Child | 13777936 | US | |
Parent | 10930048 | Aug 2004 | US |
Child | 11834602 | US |